Regeneron Receives FDA Approval for Gene Therapy Otarmeni
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 23 2026
0mins
Source: Newsfilter
- FDA Accelerated Approval: Regeneron's gene therapy Otarmeni has received FDA accelerated approval, becoming the first gene therapy for OTOF-related hearing loss, marking a new era in treating genetic hearing loss and expected to significantly improve patients' quality of life.
- Clinical Trial Results: In the CHORD trial, 80% of participants achieved hearing improvements within 24 weeks, and 42% achieved normal hearing by 48 weeks, demonstrating the therapy's efficacy and potential for widespread application.
- Innovative Treatment: Otarmeni restores hearing by delivering a functional OTOF gene into the cochlea, providing a novel treatment option, particularly significant for the approximately 50 newborns affected by OTOF-related hearing loss each year, highlighting its clinical importance.
- Free Provision: Regeneron commits to providing Otarmeni at no cost to eligible patients in the U.S., reflecting the company's dedication to improving patient lives and potentially driving broader adoption of gene therapies among diverse populations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REGN
Wall Street analysts forecast REGN stock price to rise
22 Analyst Rating
16 Buy
6 Hold
0 Sell
Moderate Buy
Current: 616.180
Low
637.00
Averages
808.50
High
1057
Current: 616.180
Low
637.00
Averages
808.50
High
1057
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sensorion Selects SENS-601 as Lead Program for Hearing Loss Treatment
- Program Selection and Adjustment: Sensorion SA announced the selection of SENS-601 as the lead program for treating GJB2-related hearing loss while discontinuing the Audiogene trial for SENS-501, resulting in a more than 15% drop in stock price on Wednesday.
- Gene Therapy Potential: SENS-601 is an AAV-based gene therapy designed to treat GJB2-related hearing loss, with the potential to address pediatric congenital deafness and early-onset presbycusis in adults, filling a market gap with no currently approved therapies.
- Clinical Trial Applications: The company has applied to initiate Hearconnex clinical trials in Canada and France, receiving Fast Track designation from the French National Agency for Medicines and Health Products Safety, aimed at evaluating the safety and efficacy of SENS-601 in pediatric patients.
- Resource Reallocation: Following the FDA approval of Regeneron's Otarmeni gene therapy, Sensorion opted to redirect resources towards the development of SENS-601, demonstrating the company's strong commitment to addressing GJB2-related hearing loss treatment.
See More
Pomerantz LLP Investigates Regeneron for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Regeneron Pharmaceuticals and its executives have engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to legal repercussions.
- Disappointing Clinical Trial Results: On May 15, 2026, Regeneron announced that its Phase 3 trial for treating advanced melanoma failed to achieve statistical significance on the primary endpoint, potentially impacting the market prospects of its drug candidates.
- Significant Stock Price Drop: Following the disappointing trial results, Regeneron's stock price fell by $68.57, or 9.82%, closing at $629.68 on May 16, 2026, reflecting market concerns about the company's future performance.
- Potential Legal Consequences: The investigation may lead to a class action lawsuit, with Pomerantz LLP, a prominent securities litigation firm, potentially seeking compensation for affected investors, thereby increasing the legal risks faced by the company.
See More
Parabilis Medicines Plans $476M IPO Amid Regeneron Collaboration
- Fundraising Plan: Parabilis Medicines aims to raise up to $476 million through its initial public offering (IPO) in the U.S., with shares priced between $17.00 and $19.00, potentially reaching $476.4 million if underwriters fully exercise their overallotment option.
- Equity Offering: The company plans to issue 25 million shares of common stock, expecting net proceeds of $413.6 million at the midpoint, which will significantly support its ongoing research and market expansion efforts.
- Valuation Outlook: At the top of the IPO price range, Parabilis could achieve a valuation of up to $2.2 billion, establishing a strong market foundation for its future developments in cancer therapies.
- Collaboration Context: Regeneron has agreed to purchase approximately $75 million in company shares at a 10% discount, as part of a concurrent private placement linked to a research collaboration worth up to $2.3 billion, reflecting confidence in Parabilis's future potential.
See More
CytomX Expands Collaboration with Regeneron Worth Up to $4B
- Collaboration Expansion: CytomX Therapeutics has expanded its collaboration with Regeneron Pharmaceuticals to a potential value of up to $4 billion, highlighting the depth of their partnership in cancer therapeutics.
- Funding Injection: CytomX will receive $37 million for nominating two additional targets selected by Regeneron for clinical development, which not only enhances its liquidity but also supports subsequent research efforts.
- Target Selection Opportunity: Regeneron will have the option to select up to six additional targets, a flexibility that could accelerate the development of new therapies, thereby enhancing CytomX's competitive position in the market.
- Potential Revenue: The expanded agreement includes payments linked to target nomination, clinical, and commercial milestones, and CytomX will also be eligible for tiered royalties based on global net sales, further strengthening its long-term profitability.
See More
Pomerantz LLP Investigates Regeneron for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Regeneron and its executives have engaged in securities fraud or other unlawful business practices, raising serious concerns about corporate governance and investor rights.
- Poor Clinical Trial Results: On May 15, 2026, Regeneron announced that its Phase 3 trial of the LAG-3 inhibitor fianlimab in combination with the PD-1 inhibitor cemiplimab failed to achieve statistical significance for the primary endpoint of progression-free survival (PFS), indicating potential risks in its R&D direction.
- Significant Stock Price Drop: Following the trial results, Regeneron's stock price fell by $68.57, or 9.82%, closing at $629.68 on May 16, 2026, reflecting market concerns about the company's future prospects.
- Potential Legal Action: Due to the stock price decline, investors may face losses, prompting Pomerantz LLP to encourage affected investors to contact them to join the class action, indicating increasing legal risks for the company.
See More
WHO Recommends Maftivimab for Ebola Treatment Evaluation
- Clinical Trial Recommendation: The WHO's Therapeutics Advisory Group has recommended Regeneron's Maftivimab for prioritized evaluation to address the Bundibugyo ebolavirus outbreak in the DRC and Uganda, highlighting the urgency of the public health crisis.
- Drug Background: Maftivimab is one of three antibodies in Inmazeb, the first FDA-approved treatment for infections caused by the Zaire ebolavirus, showing broad in-vitro activity against multiple Ebola species, although it has not yet been tested in vivo as a monotherapy.
- Patient Usage: Hundreds of patients have already received Maftivimab as part of Inmazeb, which has demonstrated an acceptable safety profile, indicating its potential in combating Ebola outbreaks.
- Company Coordination Efforts: Regeneron is closely coordinating with the U.S. Department of Health and Human Services and WHO as clinical evaluations progress, emphasizing its history of rapidly delivering medical solutions during global health crises, thereby enhancing its reputation in public health.
See More
Sensorion Selects SENS-601 as Lead Program for Hearing Loss Treatment
- Program Selection and Adjustment: Sensorion SA announced the selection of SENS-601 as the lead program for treating GJB2-related hearing loss while discontinuing the Audiogene trial for SENS-501, resulting in a more than 15% drop in stock price on Wednesday.
- Gene Therapy Potential: SENS-601 is an AAV-based gene therapy designed to treat GJB2-related hearing loss, with the potential to address pediatric congenital deafness and early-onset presbycusis in adults, filling a market gap with no currently approved therapies.
- Clinical Trial Applications: The company has applied to initiate Hearconnex clinical trials in Canada and France, receiving Fast Track designation from the French National Agency for Medicines and Health Products Safety, aimed at evaluating the safety and efficacy of SENS-601 in pediatric patients.
- Resource Reallocation: Following the FDA approval of Regeneron's Otarmeni gene therapy, Sensorion opted to redirect resources towards the development of SENS-601, demonstrating the company's strong commitment to addressing GJB2-related hearing loss treatment.
See More
Pomerantz LLP Investigates Regeneron for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Regeneron Pharmaceuticals and its executives have engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to legal repercussions.
- Disappointing Clinical Trial Results: On May 15, 2026, Regeneron announced that its Phase 3 trial for treating advanced melanoma failed to achieve statistical significance on the primary endpoint, potentially impacting the market prospects of its drug candidates.
- Significant Stock Price Drop: Following the disappointing trial results, Regeneron's stock price fell by $68.57, or 9.82%, closing at $629.68 on May 16, 2026, reflecting market concerns about the company's future performance.
- Potential Legal Consequences: The investigation may lead to a class action lawsuit, with Pomerantz LLP, a prominent securities litigation firm, potentially seeking compensation for affected investors, thereby increasing the legal risks faced by the company.
See More
Parabilis Medicines Plans $476M IPO Amid Regeneron Collaboration
- Fundraising Plan: Parabilis Medicines aims to raise up to $476 million through its initial public offering (IPO) in the U.S., with shares priced between $17.00 and $19.00, potentially reaching $476.4 million if underwriters fully exercise their overallotment option.
- Equity Offering: The company plans to issue 25 million shares of common stock, expecting net proceeds of $413.6 million at the midpoint, which will significantly support its ongoing research and market expansion efforts.
- Valuation Outlook: At the top of the IPO price range, Parabilis could achieve a valuation of up to $2.2 billion, establishing a strong market foundation for its future developments in cancer therapies.
- Collaboration Context: Regeneron has agreed to purchase approximately $75 million in company shares at a 10% discount, as part of a concurrent private placement linked to a research collaboration worth up to $2.3 billion, reflecting confidence in Parabilis's future potential.
See More
CytomX Expands Collaboration with Regeneron Worth Up to $4B
- Collaboration Expansion: CytomX Therapeutics has expanded its collaboration with Regeneron Pharmaceuticals to a potential value of up to $4 billion, highlighting the depth of their partnership in cancer therapeutics.
- Funding Injection: CytomX will receive $37 million for nominating two additional targets selected by Regeneron for clinical development, which not only enhances its liquidity but also supports subsequent research efforts.
- Target Selection Opportunity: Regeneron will have the option to select up to six additional targets, a flexibility that could accelerate the development of new therapies, thereby enhancing CytomX's competitive position in the market.
- Potential Revenue: The expanded agreement includes payments linked to target nomination, clinical, and commercial milestones, and CytomX will also be eligible for tiered royalties based on global net sales, further strengthening its long-term profitability.
See More
Pomerantz LLP Investigates Regeneron for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Regeneron and its executives have engaged in securities fraud or other unlawful business practices, raising serious concerns about corporate governance and investor rights.
- Poor Clinical Trial Results: On May 15, 2026, Regeneron announced that its Phase 3 trial of the LAG-3 inhibitor fianlimab in combination with the PD-1 inhibitor cemiplimab failed to achieve statistical significance for the primary endpoint of progression-free survival (PFS), indicating potential risks in its R&D direction.
- Significant Stock Price Drop: Following the trial results, Regeneron's stock price fell by $68.57, or 9.82%, closing at $629.68 on May 16, 2026, reflecting market concerns about the company's future prospects.
- Potential Legal Action: Due to the stock price decline, investors may face losses, prompting Pomerantz LLP to encourage affected investors to contact them to join the class action, indicating increasing legal risks for the company.
See More
WHO Recommends Maftivimab for Ebola Treatment Evaluation
- Clinical Trial Recommendation: The WHO's Therapeutics Advisory Group has recommended Regeneron's Maftivimab for prioritized evaluation to address the Bundibugyo ebolavirus outbreak in the DRC and Uganda, highlighting the urgency of the public health crisis.
- Drug Background: Maftivimab is one of three antibodies in Inmazeb, the first FDA-approved treatment for infections caused by the Zaire ebolavirus, showing broad in-vitro activity against multiple Ebola species, although it has not yet been tested in vivo as a monotherapy.
- Patient Usage: Hundreds of patients have already received Maftivimab as part of Inmazeb, which has demonstrated an acceptable safety profile, indicating its potential in combating Ebola outbreaks.
- Company Coordination Efforts: Regeneron is closely coordinating with the U.S. Department of Health and Human Services and WHO as clinical evaluations progress, emphasizing its history of rapidly delivering medical solutions during global health crises, thereby enhancing its reputation in public health.
See More
